New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
08:17 EDTCELGAcceleron Pharma and Celgene initiate phase 2 study of ACE-536
Acceleron Pharma announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes, or MDS. MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia. Acceleron is developing ACE-536 in a global collaboration with Celgene. Acceleron earned a $10M milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200M for the ACE-536 program.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use